Home › Cancer (all types) › NCT07698314
A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer
Recruiting
Myo-EXERTBC: A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer
Who can join
Ages 20 to 89 · Women
Full eligibility criteria
Inclusion Criteria: 1. Age 20-89 years 2. Women prescribed exercise as a SOC 3. Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast 4. Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed. 5. Women with \> 3 months of resistance training experience under expert guidance at the Allegheny Health Network Exercise Oncology Center Exclusion Criteria: 1. Any current treatment with cytotoxic chemotherapy for breast cancer 2. Inability to safely engage in group sessions of resistance training as deemed by study PI 3. Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training 4. Pregnant women 5. Males
About the study
In this pilot study, the investigators will assess the changes in myokine production based on several different exercise regimens.
What is being tested
- Conditioning Resistance Training (behavioral)
- Strength Resistance Training (behavioral)
- Hypertrophy Resistance Training (behavioral)
Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Participants: 21 · Started: Jul 6, 2026
Contact the study team
- Clinical Trials Contact · Phone: 412-330-6151
Official record on ClinicalTrials.gov — NCT07698314
Locations in the U.S.
| Pennsylvania | AHN Allegheny General Hospital, Pittsburgh (Not yet recruiting) Allegheny General Hospital, Pittsburgh |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.